Localized 1H-NMR Spectroscopy in Patients with Fibromyalgia: a Controlled Study of Changes in Cerebral Glutamate/glutamine, Inositol, Choline, and N-acetylaspartate
Overview
Authors
Affiliations
Introduction: The purpose of this study was to investigate whether single-voxel (SV) proton magnetic resonance spectroscopy (MRS), diffusion-weighted imaging (DWI), and diffusion tensor imaging (DTI) detected differences between fibromyalgia (FM) patients and healthy controls. We also searched for correlations between neuroimaging abnormalities and neuropsychological variables.
Methods: Ten patients with FM and 10 gender- and age-matched control subjects were studied. A neuropsychological examination, DWI, DTI, and proton MRS were performed on the brain areas known to be associated with pain processing.
Results: Compared with healthy controls, FM patients had significantly higher levels of glutamate + glutamine (Glx) (mean ± SD, 10.71 ± 0.50 arbitrary institutional units versus 9.89 ± 1.04; P = 0.049) and higher glutamate + glutamine/creatine (Glx/Cr) ratios (1.90 ± 0.12 versus 1.72 ± 0.23; P = 0.034) in the posterior gyrus. Myoinositol (Ins) levels of the right and left hippocampi were significantly lower in FM patients (4.49 ± 0.74 versus 5.17 ± 0.62; P = 0.008 and 4.91 ± 0.85 versus 6.09 ± 0.78; P = 0.004, respectively). In FM patients, decreased myoinositol/creatine (Ins/Cr) ratios were found in the left sensorimotor area (P = 0.05) and the left hippocampus (P = 0.002) and lower levels of choline (P = 0.019) and N-acetyl aspartate + N-acetyl aspartyl glutamate (NAA + NAG) (P = 0.034) in the left hippocampus. Significant correlations between depression, pain, and global function and the posterior gyrus Glx levels and Glx/Cr ratios were observed.
Conclusions: Glx within the posterior gyrus could be a pathologic factor in FM. Hippocampal dysfunction may be partially responsible for the depressive symptoms of FM. Additional studies with larger samples are required to confirm these preliminary data.
Baris E, Topaloglu I, Akalin E, Hamurtekin E, Kabaran S, Gelal A BMC Musculoskelet Disord. 2025; 26(1):97.
PMID: 39893410 PMC: 11786483. DOI: 10.1186/s12891-025-08337-0.
Bautin P, Fortier M, Sean M, Little G, Martel M, Descoteaux M Pain. 2025; 166(2):243-261.
PMID: 39793098 PMC: 11726505. DOI: 10.1097/j.pain.0000000000003345.
Shrivastava M, Ye L Int J Oral Sci. 2023; 15(1):58.
PMID: 38155153 PMC: 10754947. DOI: 10.1038/s41368-023-00254-z.
Pain Biomarkers in Fibromyalgia Syndrome: Current Understanding and Future Directions.
Favretti M, Iannuccelli C, Di Franco M Int J Mol Sci. 2023; 24(13).
PMID: 37445618 PMC: 10341963. DOI: 10.3390/ijms241310443.
Orally Administered Bifidobacterium adolescentis Diminishes Serum Glutamate Concentration in Mice.
Royo F, Tames H, Bordanaba-Florit G, Cabrera D, Azparren-Angulo M, Garcia-Vallicrosa C Microbiol Spectr. 2023; 11(4):e0506322.
PMID: 37347184 PMC: 10433951. DOI: 10.1128/spectrum.05063-22.